RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.

doi:10.1016/j.jtho.2020.01.006

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Apr 2020

Solomon Benjamin J, Tan Lavinia, Lin Jessica J, Wong Stephen Q, Hollizeck Sebastian, Ebata Kevin, Tuch Brian B, Yoda Satoshi, Gainor Justin F, Sequist Lecia V, Oxnard Geoffrey R, Gautschi Oliver, Drilon Alexander, Subbiah Vivek, Khoo Christine, Zhu Edward Y, Nguyen Michele, Henry Dahlia, Condroski Kevin R, Kolakowski Gabrielle R, Gomez Eliana, Ballard Joshua, Metcalf Andrew T, Blake James F, Dawson Sarah-Jane, Blosser Wayne, Stancato Louis F, Brandhuber Barbara J, Andrews Steve, Robinson Bruce G, Rothenberg S Michael

Abstract excerpt

INTRODUCTION: Novel rearranged in transfection (RET)-specific tyrosine kinase inhibitors (TKIs) such as selpercatinib (LOXO-292) have shown unprecedented efficacy in tumors positive for RET fusions or mutations, notably RET fusion-positive NSCLC and RET-mutated medullary thyroid cancer (MTC). However, the mechanisms of resistance to these agents have not yet been described. METHODS: Analysis was performed of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-ret

Share to Pyrazoles

Share to Pyridines

Share to Solvents

Share to Transfection

Source

Open in PubMed Open full text

Identifiers

PMID: 31988000
DOI: 10.1016/j.jtho.2020.01.006
PMCID: PMC7430178

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.PMID 31988000Read ↗

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.Semantic proximity Read ↗

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.Semantic proximity Read ↗

Discovery of 7-(1-methyl-1H-pyrazol-4-yl)-1,6-naphthyridine derivatives as potent inhibitors of rearranged during transfection (RET) and RET solvent-front mutants for overcoming selpercatinib resistance.Semantic proximity Read ↗

Progress and challenges in RET-targeted cancer therapy.Semantic proximity Read ↗

Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers.Semantic proximity Read ↗

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.Semantic proximity Read ↗

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.Semantic proximity Read ↗

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.Semantic proximity Read ↗

Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based InhibitorsSemantic proximity Read ↗

Targeting RET alterations in cancer: Recent progress and future directions.Semantic proximity Read ↗

Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.Semantic proximity Read ↗

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.